No Data
No Data
Genmab Advances Share Buy-back Program With Significant Repurchases
Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Announces Target Price $29
Analysts Have Conflicting Sentiments on These Healthcare Companies: Geron (GERN), Genmab (GMAB) and Elanco Animal Health (ELAN)
Express News | Genmab : Leerink Partners Raises Target Price to $29 From $27
Demonstrating resilience under Trump's tariff threats, Johnson & Johnson (JNJ.US) raises its full-year revenue guidance.
Johnson & Johnson announced its financial results for the first quarter.
Genmab Announces Net Sales of DARZALEX (Daratumumab) for First Quarter of 2025
Lnova : whoa!